Astellas Pharma Overview
- Founded
-
1894
- Status
-
Public
- Employees
-
14,522
- Stock Symbol
-
4503
- Investments
-
33
- Share Price
-
$15.25
- (As of Tuesday Closing)
Astellas Pharma General Information
Description
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.
Contact Information
- 2-5-1, Nihonbashi-Honcho
- Chuo-ku
- Tokyo, 103-8411
- Japan
Astellas Pharma Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $15.25 | $15.34 | $12.87 - $16.42 | $27.8B | 1.81B | 5.65M | $0.57 |
Astellas Pharma Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
|---|---|---|---|---|
| EV | 26,840,820 | 28,035,433 | 29,259,967 | 27,636,821 |
| Revenue | 11,172,221 | 11,537,524 | 11,783,609 | 11,963,701 |
| EBITDA | 2,065,145 | 2,095,097 | 1,968,163 | 2,854,593 |
| Net Income | 1,038,135 | 1,104,526 | 1,137,208 | 1,797,172 |
| Total Assets | 19,172,881 | 19,110,478 | 20,610,210 | 21,422,259 |
| Total Debt | 2,510,304 | 2,301,144 | 3,147,188 | 4,394,981 |
Astellas Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Astellas Pharma Comparisons
Industry
Financing
Details
000000
000
Astellas Pharma Competitors (38)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Coherus Biosciences | Formerly VC-backed | Redwood City, CA | 000 | 00000 | 000000000 | 00000 |
| 000 | Corporation | Parkville, Australia | 00000 | 00.000 | 000000000 | 00.000 |
| 000000000 | Corporation | Mumbai, India | 0000 | 000000000 | ||
| 000000 | Corporation | North Chicago, IL | 00000 | 00.000 | 00000000000 | 00.000 |
| 0000 0000000000000 | Corporate Backed or Acquired | Petah Tikva, Israel | 00000 | 00000 | 00000000000 | 00000 |
Astellas Pharma Patents
Astellas Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-6931880-B1 | Electrocardiogram analysis support device, program, electrocardiogram analysis support method, and electrocardiogram analysis support system | Active | 24-Mar-2021 | 0 | |
| JP-2022148632-A | Electrocardiogram analysis support device, program, electrocardiogram analysis support method and electrocardiogram analysis support system | Active | 24-Mar-2021 | ||
| JP-2022148631-A | Electrocardiogram analysis support device, program, electrocardiogram analysis support method and electrocardiogram analysis support system | Active | 24-Mar-2021 | ||
| JP-7032747-B1 | Ecg analysis support device, program, ecg analysis support method, and ecg analysis support system | Active | 24-Mar-2021 | 0 | |
| JP-7169729-B1 | Quinazoline compounds for inducing degradation of g12d mutant kras protein | Active | 15-Feb-2021 | 0 |
Astellas Pharma Executive Team (30)
Astellas Pharma Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 0000000 | Astellas Pharma | Director | 000 0000 |
| 000000 000000000 | Self | Board Member | 000 0000 |
| 00000 00000000 00. | Astellas Pharma | Chief Executive Officer & Board Member | 000 0000 |
| 00000 0000000 | Astellas Pharma | Board Member & Executive Vice President | 000 0000 |
| 00000 000000000 | Astellas Pharma | Board Member | 000 0000 |
Astellas Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Astellas Pharma Investments & Acquisitions (33)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000 | 29-Apr-2023 | 0000000000 | 00.00 | Biotechnology | 000000000 |
| 000 0000000 ( | 03-Mar-2023 | 000000000 | 0000 | Buildings and Property | |
| 000000000 | 08-Aug-2022 | 00000 | 00000 | Other Healthcare Services | |
| 0000000000 | 17-Feb-2021 | 00000 0000 | 000.00 | Other Commercial Services | |
| Beijing Tianyuankang Pharmaceutical | 18-Dec-2020 | Merger/Acquisition | Pharmaceuticals |
Astellas Pharma Subsidiaries (11)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Xyphos Biosciences | Biotechnology | South San Francisco, CA | 2017 |
| 0000000 0000000000 | Biotechnology | Cambridge, MA | 0000 |
| 000000000 00000 | Biotechnology | Seattle, WA | 0000 |
| 00000 000000000000 | Drug Discovery | Cambridge, United Kingdom | 0000 |
| 0000000000 | Drug Discovery | Cambridge, MA | 0000 |
Astellas Pharma ESG
Risk Overview
Risk Rating
Updated November, 03, 2022
20.88 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,480
Rank
Percentile
Pharmaceuticals
Industry
00 of 905
Rank
Percentile
Pharmaceuticals
Subindustry
0. of 435
Rank
Percentile
Astellas Pharma Exits (6)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000 000 | 02-Jun-2015 | 00000 00000 00 | 000.00 | Completed |
|
| 000000 000 | 29-May-2015 | 00000 0000000 | 00000 | Completed |
|
| 00000 00000000 000 | 01-Oct-2013 | 00000 0000000 | Completed |
|
|
| 0000000 (000000000 | 22-Jun-2009 | 000000000 00000 00 | 0000 | Completed |
|
| FibroGen | 10-Jan-2007 | Later Stage VC | 0000 | Completed |
|